[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@ArndtVogel Avatar @ArndtVogel Arndt Vogel

Arndt Vogel posts on X about matterhorn, iii, mos, promising the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence currencies XXXXX% travel destinations XXXX% cryptocurrencies XXXX%

Social topic influence matterhorn 5.88%, iii 5.88%, mos 5.88%, promising XXXX%

Top accounts mentioned or mentioned by @myesmo @easledu @medwatchkate @dryukselurun @ilcanews @jcoasco @ilca @yjanjigianmd @larvol @neerajresearch @drangelalamarca @dianaroseroo @lorenzarimassa @basgrootkoerkam @michaelkuanchi1 @renohemonc

Top Social Posts #

Top posts by engagements in the last XX hours

"MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma #ESMO25 #ESMOAmbassadors 👉 pCR: XX% MPR: XX% any: XX% 👉 OS: HR: 0.78; 36-mo OS: XX vs XX% 🧐OS improved independent of TAP better in responders new SOC @myesmo"
X Link @ArndtVogel 2025-10-17T12:12Z 8830 followers, 15.6K engagements

"PARERE trial: Panitumumab retreatment followed by regorafenib vs the reverse sequence in chemorefractory mCRC with RAS/ BRAF WT ctDNA #ESMO25 #ESMOAmbassadors 👉 mOS: XXXX vs 11.7mo 👉Better PFS for pani in both arms 🧐negative trial but rechallenge is an option in 4L @myesmo"
X Link @ArndtVogel 2025-10-18T13:48Z 8830 followers, 4860 engagements

"Comparison of outcomes in clinical trials of locally advanced dMMR colon cancer: FOxTROT and NICHE-2 #ESMO25 #ESMOAmbassadors 👉 patient based comparison 👉 Final coffin nail for CTx 👉 Can we omit surgery next 🧐 Amazing efficacy for ICI in MSI CRC @myesmo"
X Link @ArndtVogel 2025-10-18T13:12Z 8830 followers, 5241 engagements

"TALENTop phs 3: Liver resection versus continued atezolizumab plus bevacizumab in locally advanced HCC after atezo/bev treatment #ESMO25 #ESMOAmbassadors 👉 EFS: XX vs vs XX mo 🧐great study design: response adapted subsequent therapy. Multimodal therapy in HCC is key @myesmo @EASLedu @ILCAnews"
X Link @ArndtVogel 2025-10-20T09:14Z 8830 followers, 3392 engagements

"HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D PDAC #ESMO25 #ESMOAmbassadors 👉 ORR: XX% DCR XX% 👉 6mo PFS rate: XX% 👉 manageable safety 🧐 KRASi are the future in 1L @myesmo"
X Link @ArndtVogel 2025-10-19T16:56Z 8834 followers, 5298 engagements

"🔥Presidential Session🔥 AGITG DYNAMIC-III trial : ctDNA-guided adjuvant CTx de-escalation in stage III CRC analysis of the ctDNA-cohort #ESMO25 #ESMOAmbassadors 👉 markedly reduced oxaliplatin exposure 👉 non-inferiority not shown specifically in high risk pts 👉 ctDNA burden prognostic 🧐feasible but not yet there.predictive uncertainty @myesmo"
X Link @ArndtVogel 2025-10-20T15:13Z 8833 followers, 4345 engagements

"PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II CRC patients #ESMO25 #ESMOAmbassadors 👉ctDNA trajectories define prognosis 👉 3yr-DFS: XX (-) vs XX% (+) 🧐Very innovative trail design ctDNA guided ACT is the future @myesmo"
X Link @ArndtVogel 2025-10-18T12:56Z 8834 followers, 10.9K engagements

"CARES-009: Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma #ESMO25 #ESMOAmbassadors 👉 EFS: XX vs XX mo 👉 DFS: XX vs XX mo 👉 MPR: XX vs X% 🧐Very promising results neoadjuvant strategies will be the future in HCC @myesmo @EASLedu @ilca"
X Link @ArndtVogel 2025-10-19T10:00Z 8834 followers, 9643 engagements

"Neoadjuvant Toripalimab Plus Lenvatinib and GEMOX in Resectable High-Risk iCCCA: Phase II-III Trial #ESMO25 #ESMOAmbassadors 👉 EFS: X vs 18mo 🧐Strong signal for neoadjuvant therapy in BTC more trials to come. @myesmo"
X Link @ArndtVogel 2025-10-20T09:27Z 8834 followers, 6133 engagements

"CASSANDRA phs 3: short vs long-course pre-operative CTx for stage I-III PDAC #ESMO25 #ESMOAmbassadors 👉 No difference in EFS between short vs long pre-OP CTx 👉but high CA19.9 response N0 resection dose intensity 🧐the jury is still out for best neoadjuvant approach @myesmo"
X Link @ArndtVogel 2025-10-20T09:35Z 8834 followers, 4371 engagements

"🔥Presidential Session🔥 FORTITUDE-101 phase III: Bemarituzumab plus CTx for advanced FGFR2b+ G/GEJC #ESMO25 #ESMOAmbassadors 👉mOS:17.9 vs XXXX mo but less benefit w/ follow up 👉Ocular AEs may be a concern 🧐Positive trial but not practice changing 👏great discussion by @YJanjigianMD @myesmo"
X Link @ArndtVogel 2025-10-20T16:13Z 8833 followers, 7272 engagements